Compare NRIM & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRIM | HELP |
|---|---|---|
| Founded | 1990 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.6M | 712.2M |
| IPO Year | 2002 | 2020 |
| Metric | NRIM | HELP |
|---|---|---|
| Price | $27.25 | $11.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 144.0K | ★ 2.1M |
| Earning Date | 04-22-2026 | 07-01-2026 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $255,581,000.00 | N/A |
| Revenue This Year | $4.98 | N/A |
| Revenue Next Year | $7.40 | N/A |
| P/E Ratio | $20.95 | ★ N/A |
| Revenue Growth | ★ 30.43 | N/A |
| 52 Week Low | $19.60 | $3.76 |
| 52 Week High | $95.61 | $11.95 |
| Indicator | NRIM | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 53.84 | 73.76 |
| Support Level | $25.99 | $4.41 |
| Resistance Level | $28.08 | N/A |
| Average True Range (ATR) | 0.51 | 0.80 |
| MACD | -0.02 | 0.22 |
| Stochastic Oscillator | 60.33 | 99.15 |
Northrim BanCorp Inc is a bank holding company operating through three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. The Community Banking segment, which generates the majority of revenue, provides loan and deposit products to business and consumer customers in its market areas. The Home Mortgage Lending segment focuses on the origination and sale of mortgage loans for one-to-four family residential properties, mortgage loan servicing for certain loans sold, and investment in selected residential mortgage loans. The Specialty Finance segment provides factoring, asset-based lending, and alternative working capital solutions to small and medium-sized enterprises and includes SCF and Northrim Funding Services.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.